SEARCH

SEARCH BY CITATION

References

  • 1
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer. I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:53645.
  • 2
    Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995;141:6809.
  • 3
    Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:81019.
  • 4
    Van Ballegooijen M, Van Den Akker-van Marle E, Patnick J, Lynge E, Arbyn M, Anttila A, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000;36:217788.
  • 5
    Apgar BS, Zoschnick L, Wright TC Jr. The 2001 Bethesda System terminology. Am Fam Physician 2003;68:19928.
  • 6
    Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002;46:61929.
  • 7
    Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Van Der Linden HC, Runsink AP, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398404.
  • 8
    Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:161623.
  • 9
    Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003;127:9469.
  • 10
    Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:138392.
  • 11
    Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:51827.
  • 12
    Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94101.
  • 13
    Klaassen CH, Prinsen CF, De Valk HA, Horrevorts AM, Jeunink MA, Thunnissen FB. DNA microarray format for detection and subtyping of human papillomavirus. J Clin Microbiol 2004;42:215260.
  • 14
    Klaassen CH, Jeunink MA, Prinsen CF, Ruers TJ, Tan AC, Strobbe LJ, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003;49:11857.
  • 15
    Prinsen CF, Klaassen CH, Thunnissen FB. Microarray as a model for quantitative visualization chemistry. Appl Immunohistochem Mol Morphol 2003;11:16873.
  • 16
    Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99(3 Suppl 1):S711.
  • 17
    Clavel C, Cucherousset J, Lorenzato M, Caudroy S, Nou JM, Nazeyrollas P, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer 2004;90:18038.
  • 18
    Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:4652.
  • 19
    Denise Zielinski G, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, De Schipper FA, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001;195:3006.
  • 20
    Dalstein V, Riethmuller D, Sautiere JL, Pretet JL, Kantelip B, Schaal JP, et al. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 2004;40:122532.
  • 21
    Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WK, Hurley LB, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol 1999;30:81625.
  • 22
    Petry KU, Menton S, Menton M, Van Loenen-Frosch F, De Carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:15707.
  • 23
    Bais AG, Rebolj M, Snijders PJ, De Schipper FA, Van Der Meulen DA, Verheijen RH, et al. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer 2005;116:1229.
  • 24
    Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:3049.
  • 25
    Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004;91:8491.
  • 26
    Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:61931.
  • 27
    Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 2006;113:13037.
  • 28
    Zielinski GD, Bais AG, Helmerhorst ThJ, Verheijen RHM, De Schipper FA, Snijders PJF, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:54353.
  • 29
    Castle PE, Hildesheim A, Schiffman M, Gaydos CA, Cullen A, Herrero R, et al. Stability of archived liquid-based cytologic specimens. Cancer 2003;99:3202.
  • 30
    Baay M, Verhoeven V, Wouters K, Lardon F, Van Damme P, Avonts D, et al. The prevalence of the human papillomavirus in cervix and vagina in low-risk and high-risk populations. Scand J Infect Dis 2004;36:4569.
  • 31
    Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004;42:24705.
  • 32
    Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:94253.
  • 33
    Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:218993.
  • 34
    Van Der Graaf Y, Molijn A, Doornewaard H, Quint W, Van Doorn LJ, Van Den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol 2002;156:15864.
  • 35
    Snijders PJ, Van Den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:16.
  • 36
    Kjaer SK, Van Den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.
  • 37
    Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, et al. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 2004;73:2628.
  • 38
    Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004;57:6872.
  • 39
    Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:2217.